# Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis

> **NCT02903212** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 22 (estimated)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** Autologous apoptotic cells injection

## Key facts

- **NCT ID:** NCT02903212
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903212, "Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02903212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*